Literature DB >> 1673078

Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, beta-endorphin and somatostatin.

C B Nemeroff1, G Bissette, H Akil, M Fink.   

Abstract

The CSF concentrations of CRF, somatostatin and beta-endorphin were determined in nine patients who fulfilled DSM-III criteria for major depression with psychotic features. CSF samples were obtained at baseline in the depressed state, and again after a course of ECT. Concentrations of both CRF and beta-endorphin decreased after ECT, while the concentration of somatostatin increased, although the latter difference did not attain statistical significance. The increase in CSF concentrations of CRF and beta-endorphin in depressed patients is therefore seen to be state-dependent.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673078     DOI: 10.1192/bjp.158.1.59

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  38 in total

Review 1.  Evidence for the role of corticotropin-releasing factor in major depressive disorder.

Authors:  R Parrish Waters; Marion Rivalan; D A Bangasser; J M Deussing; M Ising; S K Wood; F Holsboer; Cliff H Summers
Journal:  Neurosci Biobehav Rev       Date:  2015-08-10       Impact factor: 8.989

2.  Social supports and serotonin transporter gene moderate depression in maltreated children.

Authors:  Joan Kaufman; Bao-Zhu Yang; Heather Douglas-Palumberi; Shadi Houshyar; Deborah Lipschitz; John H Krystal; Joel Gelernter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-11-24       Impact factor: 11.205

3.  Interaction of stress, corticotropin-releasing factor, arginine vasopressin and behaviour.

Authors:  Eléonore Beurel; Charles B Nemeroff
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 4.  Endocrine disturbances in depression.

Authors:  M A Tichomirowa; M E Keck; H J Schneider; M Paez-Pereda; U Renner; F Holsboer; G K Stalla
Journal:  J Endocrinol Invest       Date:  2005-01       Impact factor: 4.256

Review 5.  Role of corticotropin releasing factor in anxiety disorders: a translational research perspective.

Authors:  Victoria B Risbrough; Murray B Stein
Journal:  Horm Behav       Date:  2006-07-25       Impact factor: 3.587

6.  CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors.

Authors:  D W Schulz; R S Mansbach; J Sprouse; J P Braselton; J Collins; M Corman; A Dunaiskis; S Faraci; A W Schmidt; T Seeger; P Seymour; F D Tingley; E N Winston; Y L Chen; J Heym
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-17       Impact factor: 11.205

Review 7.  Perinatal exposure to bisphenol A at the intersection of stress, anxiety, and depression.

Authors:  Kimberly R Wiersielis; Benjamin A Samuels; Troy A Roepke
Journal:  Neurotoxicol Teratol       Date:  2020-04-11       Impact factor: 3.763

Review 8.  Pituitary Adenylate Cyclase-Activating Peptide (PACAP) Signaling and the Dark Side of Addiction.

Authors:  Olivia W Miles; Victor May; Sayamwong E Hammack
Journal:  J Mol Neurosci       Date:  2018-08-03       Impact factor: 3.444

Review 9.  The CRF system, stress, depression and anxiety-insights from human genetic studies.

Authors:  E B Binder; C B Nemeroff
Journal:  Mol Psychiatry       Date:  2009-12-15       Impact factor: 15.992

10.  Persistent elevations of cerebrospinal fluid concentrations of corticotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: implications for the pathophysiology of mood and anxiety disorders.

Authors:  J D Coplan; M W Andrews; L A Rosenblum; M J Owens; S Friedman; J M Gorman; C B Nemeroff
Journal:  Proc Natl Acad Sci U S A       Date:  1996-02-20       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.